Dr. Muhammad A. Mohiuddin, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 195
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
FL license ME 79526
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- HCA Florida Osceola Hospital Kissimmee, FL
Medical groups
- Gastro Health, LLC (247 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 195
- Services billed
- 438
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 95 | 73 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 74 | 43 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 57 | 57 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 53 | 53 |
| Established patient office or other outpatient visit, 30-39 minutes | 47 | 37 |
| Biopsy of large bowel using a flexible endoscope | 30 | 30 |
| New patient office or other outpatient visit, 30-44 minutes | 30 | 30 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 25 | 25 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 13 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sucralfate Other prescribers in Kissimmee, FL | 297 |
| Pantoprazole Sodium Other prescribers in Kissimmee, FL | 286 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Kissimmee, FL | 284 |
| Esomeprazole Magnesium Other prescribers in Kissimmee, FL | 179 |
| Famotidine Other prescribers in Kissimmee, FL | 162 |
| Dicyclomine Hcl Other prescribers in Kissimmee, FL | 129 |
| Linzess (linaclotide) Other prescribers in Kissimmee, FL | 117 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Kissimmee, FL | 97 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 76 |
| Metoclopramide Hcl Other prescribers in Kissimmee, FL | 76 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 40 payments worth $815 in total to this clinician.
| AbbVie Inc. | $260 |
|---|---|
| Janssen Biotech, Inc. | $180 |
| Mallinckrodt Hospital Products Inc. | $148 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.01 |
| Genzyme Corporation | $50.66 |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.75 |
| Celltrion USA Inc. | $25.23 |
| Phathom Pharmaceuticals, Inc. | $24.69 |
| Food and Beverage | $815 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $79,937 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Sanofi US Services Inc. · Recruiting · NCT06958536 - A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)
Janssen Research & Development, LLC - A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
Sanofi US Services Inc. · Active, not recruiting · NCT06975722
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.